Mon Sep 09 15:16:08 UTC 2024: ## IMUNON to Host Ovarian Cancer R&D Day in New York City
**LAWRENCEVILLE, NJ – September 9, 2024** – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announced it will host its first Ovarian Cancer R&D Day on September 18th, 2024 at the Harvard Club in New York City. The event will focus on the company’s investigational therapy IMNN-001, currently in development for the treatment of advanced ovarian cancer.
The R&D Day will feature presentations from key opinion leaders (KOLs), including clinical study investigators, immunology and biostatistics experts, and company management. The presentations, taking place from 10:00 a.m. to 12:00 p.m. Eastern time, will cover the development program for IMNN-001, reviewing the positive topline data from the Phase 2 OVATION 2 Study. This study demonstrated that IMNN-001 treatment was associated with a 35% improvement in survival among patients with advanced disease.
The event will also explore the potential role of IMNN-001 in the treatment of advanced ovarian cancer and discuss the next steps in the development program. IMUNON encourages in-person attendance to facilitate networking and direct engagement with speakers and management. A webcast will be available for those unable to attend in person.
IMUNON’s IMNN-001 is a DNA-based immunotherapy designed to deliver safe and durable levels of cancer-fighting molecules directly to the tumor site. The company’s technology has shown promising results in previous clinical trials, particularly in the treatment of advanced epithelial ovarian cancer, which is characterized by a high risk of recurrence and poor survival rates.
This R&D Day event provides a platform for IMUNON to share its advancements in the development of IMNN-001, highlighting its potential as a novel therapeutic option for patients with advanced ovarian cancer.
First Piper 